Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled

 Court rules Medivation has no IP rights to Aragon Pharmaceuticals ARN 509 $MDVN

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $399 for 3 months access, $699 for 6 months access or $1200 for 12 months access. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals.